The financial performance of Cipla was received well by the market and it went on to touch Rs.226, very close to its high of Rs.234 and way above its new low of Rs.160.
The company has received approvals for Budesonide inhalers in Germany and Portugal, Salbutamol MDI in Denmark and Portugal, and Beclomethasone in Portugal. It is also in the process of initiating clinical trials on dry powder inhalers for the European market.
In USA, apart from the already existing 10 partners, the company has added 2 new partners. The company is also in the process of creating additional capacities at the Indore SEZ where it has four plants being put up.
Stay invested. Pharma is the new flavour of the market
source
I am holding onto my cipla shares.
ReplyDeleteFree Niche Market Ideas